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Nitric oxide (NO) modulates the biological levels of
arachidonate-derived cell signaling molecules by ei-
ther enhancing or suppressing the activity of prosta-
glandin H2 isoforms (PGHS-1 and PGHS-2). Whether
NO activates or suppresses PGHS activity is deter-
mined by alternative protein modifications mediated
by NO and NO-derived species. Here, we show that
inducible NO synthase (iNOS) and PGHS-1 co-localize
in atherosclerotic lesions of ApoE/ mouse aortae.
Immunoblotting and immunohistochemistry re-
vealed Tyr nitration in PGHS-1 in aortic lesions but
markedly less in adjacent nonlesion tissue. PGHS-2
was also found in lesions, but 3-nitrotyrosine incor-
poration was not detected. 3-Nitrotyrosine formation
in proteins is considered a hallmark reaction of per-
oxynitrite, which can form via NO-superoxide reac-
tions in an inflammatory setting. That iNOS-derived
NO is essential for 3-nitrotyrosine modification of
PGHS-1 was confirmed by the absence of 3-nitroty-
rosine in lesions from ApoE/iNOS/ mice. Mass
spectrometric studies specifically identified the active
site residue Tyr385 as a 3-nitrotyrosine modification
site in purified PGHS-1 exposed to peroxynitrite.
PGHS-mediated eicosanoid (PGE2) synthesis was
more than fivefold accelerated in cultured iNOS/
versus iNOS-expressing mouse aortic smooth muscle
cells, suggesting that iNOS-derived NO markedly sup-
presses PGHS activity in vascular cells. These results
further suggest a regulatory role of iNOS in eicosanoid
biosynthesis in human atherosclerotic lesions. (Am J
Pathol 2006, 168:349–362; DOI: 10.2353/ajpath.2006.050090)
The enzyme prostaglandin H2 synthase (PGHS, also
known as cyclooxygenase) regulates the production of
eicosanoids that modulate physiological processes in the
vessel wall, contributing to atherosclerosis and thrombo-
sis. These processes include platelet aggregation, con-
trol of vascular tone, and the local inflammatory re-
sponse. PGHS-1, the constitutive form of PGHS, is the
predominant isozyme in platelets and mediates produc-
tion of platelet thromboxane A2 (TxA2), a potent platelet
agonist and vasoconstrictor. The beneficial effect of as-
pirin in reducing cardiovascular events is often attributed
to inhibition of PGHS-1-mediated platelet TxA2.
1,2 Pros-
tacyclin (PGI2), the major product of vascular endotheli-
um,3 has opposite effects on platelet function and vas-
cular tone and may inhibit thrombus formation by
preventing platelet adhesion.4 PGHS-2, the inducible
form of PGHS, is a proinflammatory mediator that is as-
sociated with tumorigenesis and atherosclerosis.5,6 In
some settings PGHS-2 may be the major source of PGI2
under physiological conditions7 due to its induction in
endothelial cells by hemodynamic shear,8 but PGHS-1 is
also suggested to play an important role.9 The opposing
properties of PGI2 and TxA2 suggest that a balance be-
tween these compounds in the regulation of interactions
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between platelets and the vessel wall may be disrupted
during inflammation and atherosclerosis.10,11
Eicosanoid production may be modulated by the inter-
action of the nitric oxide (NO) and arachidonic acid bio-
synthetic pathways. This interaction can lead to either
stimulation or inhibition of PGHS activity, as well as al-
tered transcription of the PGHS-2 gene.12–27 Because
several different forms of nitrogen oxides (NOx) may arise
in biological systems, it is conceivable that one form of
NOx may activate PGHS whereas another form may lead
to inhibition. Indeed, in our previous studies we demon-
strated that peroxynitrite (ONOO) leads to PGHS-1 ac-
tivation whereas NO leads to inhibition.17 We also found
that ONOO can affect PGHS activity by initiating a sig-
naling cascade that leads to arachidonic acid release
and subsequent eicosanoid production.28 Another inter-
action of ONOO and PGHS leads to PGHS nitration,
which is correlated with a loss in activity.29 In this regard,
ONOO was found to nitrate-purified PGHS-1 as well as
PGHS-1 in smooth muscle cells. Importantly, nitrated
PGHS-1 has been detected in human atherosclerotic
lesions.29
Further evidence that the NO and eicosanoid biosyn-
thetic pathways are linked is supported by recently pub-
lished in vivo studies. Mice missing the gene that encodes
the inducible form of NO synthase (iNOS) demonstrated
a reduced ability to synthesize eicosanoids globally while
synthesis of thromboxane was enhanced.30 A reduction
in eicosanoid biosynthesis in inflammatory lesions was
also observed after administration of NOS inhibitors to
rats.31,32 Furthermore, inflamed brain tissue from iNOS
knockout mice also contains decreased levels of PGE2
when compared to wild-type mice.33 Taken together,
these results indicate that iNOS-derived NO, or a NO-
derived species, causes decreased biosynthesis of eico-
sanoids. In contrast, the loss or inhibition of NOS up-
regulates eicosanoid production.34–38 For example,
coronary arteries from wild-type mice vasodilate in re-
sponse to acetylcholine by a mechanism involving NO
from endothelial NOS (eNOS), but eNOS-deficient mice
respond principally by a mechanism involving PGHS.39
Such observations suggest that the PGHS pathway may
compensate to maintain near-normal coronary arterial
function in response to chronic loss of eNOS in blood
vessels. Either way, given the strong link between NO
and eicosanoid pathways, it follows that eicosanoid pro-
duction in the vessel wall may be affected during disease
states in which NO production is perturbed, such as
atherosclerosis.40,41
The apolipoprotein E-deficient (ApoE/) mouse has
been used successfully as an animal model of athero-
genesis.42 The ApoE amphipathic protein stabilizes and
solubilizes lipoprotein particles and thus plays a pivotal
role in lipoprotein trafficking. ApoE is a constituent of
chylomicrons, very low-density lipoprotein, intermediate-
density lipoprotein, and high-density lipoprotein and acts
as a ligand for the receptor-mediated clearance of these
particles.43 ApoE/ mice have plasma cholesterol levels
that are four to five times greater than normal and de-
velop atherosclerotic lesions spontaneously, even
when fed a low-cholesterol diet.42 The development of
ApoE/ mice that are also deficient in iNOS (ApoE/
iNOS/ mice) has been described.44–46 ApoE/
iNOS/ mice are normotensive and, when fed a normal
chow diet, develop atherosclerotic lesions in a manner
that is indistinguishable from ApoE/ mice.44 For this
reason, it was initially thought that iNOS-derived NO does
not influence lesion progression. However, when lesion
progression is accelerated by feeding ApoE/iNOS/
mice a Western diet, lesions are reduced in size com-
pared to ApoE/ mice.45,46 These results indicate that
iNOS-derived NO is proatherogenic.
The current study was designed to determine whether
PGHS nitration is associated with atherosclerosis in the
ApoE/ mouse model and, if so, whether nitration is
dependent on the presence of iNOS. Because iNOS/
mice in a nonatherosclerotic genetic background display
a reduced ability to synthesize eicosanoids,30 we sought
to determine whether the absence of iNOS would pro-
mote eicosanoid production in a mouse model of athero-
sclerosis. For this purpose, we cultured smooth muscle
cells from ApoE/ and ApoE/iNOS/ mice and eval-




The animal protocol used in these studies was reviewed
and approved by the Weill Medical College of Cornell
University Care and Use Committee. ApoE/iNOS/
mice were generated as described previously.44 Mice
used in these studies were derived from at least six
generations of backcross breeding to C57BL/6J mice.44
ApoE/iNOS/ heterozygote mice were bred to gener-
ate pups that were then genotyped for the iNOS allele by
Southern blot analysis. Primers that are complimentary
to portions of exon 11, exon 12, and neomycin (neo)
were used: AGAGTCCTTCATGAAGCACATGCA (exon
11), TCAGCTTCTCATTCTGCCAGATGT (exon 12), and
CAATCCATCTTGTTCAATGGCCGA (neo). The primers
were mixed one part neo, two parts exon 11, one part
exon 12. Wild-type mice contain both exons 11 and 12
and give rise to a larger band (500 bp) whereas
iNOS/ mice contain exon 11 and neomycin and give
rise to a smaller band (340 bp). iNOS/ mice give rise
to both bands.
Study Design
ApoE/iNOS/ males and females were designated
as the experimental group and ApoE/ littermates (con-
taining iNOS/) were designated the control group.
ApoE/iNOS/ pups were used as breeding mice. In
total, we have used 100 ApoE/ mice and 100
ApoE/iNOS/ mice in these studies. At 21 days, the
mice were weaned. The mice were fed a Western diet ad
libitum comprising 21.2% fat (g/100 g), 0.2% cholesterol,
and 0% cholate (Harlan Teklad, Indianapolis, IN). At 6
months, the mice in the control and experimental groups
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were sacrificed. The mice were weighed before euthana-
sia and average weights of the ApoE/ and ApoE/
iNOS/ mice (inclusive of both males and females) were
30.0  0.3 g and 29.2  0.7 g, respectively, and were not
significantly different. Aortae were removed surgically
from the cardiac origination to the iliac bifurcation and
frozen at 80°C. Using a dissecting microscope (SMZ-
1B; Nikon, Melville, NY), the aortae were cleared of fat,
connective tissues, and adventitia, and dissected into
portions representing lesions and surrounding tissue,
which were then preserved at 80°C. Lesions and sur-
rounding aortic tissue from these animals were used for
Western blot and immunoprecipitation experiments, as
described below.
Isolation of Smooth Muscle Cells from ApoE/
and ApoE/iNOS/ Mice
The isolation of vascular smooth muscle cells from
murine aortae was performed according to a published
method.47 Briefly, mice were sacrificed by CO2 as-
phyxiation and secured on a dissecting board. The
thorax and abdomen were rinsed (70% ethanol), the
skin was removed, and the thorax was opened to ex-
pose the heart and lungs. The aorta was dissected
from its origin at the left ventricle to the iliac bifurcation.
Using a syringe with a 26-gauge needle to puncture
the left ventricle, the aorta was flushed with sterile
phosphate-buffered saline (3 ml), surgically removed,
and placed in a Petri dish covered with Dulbecco’s
modified Eagle’s medium (DMEM) (50 to 100 l, con-
taining 0.25 g/ml filter-sterilized fungizone). Using a
dissecting microscope, the aorta was cleared of fat,
connective tissues, and adventitia. The aorta was
transferred to a new Petri dish, covered with DMEM (50
to 100 l, containing 10% fetal bovine serum (FBS), 1%
glutamine, 1% antibiotic-antimycotic; Invitrogen, Carls-
bad, CA), and cut into 1- to 2-mm-square pieces. The
pieces of aorta were transferred to a small tissue cul-
ture tube containing type II collagenase solution (136
g in culture medium). The tube was placed with the
cap loosely attached in a standard tissue culture incu-
bator (37°C, 5% CO2) for 4 to 6 hours. The tube was
removed from the incubator, gently agitated to resus-
pend the cells, and DMEM was added (3 ml containing
10% FBS, 1% glutamine, 1% antibiotic-antimycotic).
The suspension was transferred to a conical polypro-
pylene tube (15 ml) and centrifuged at 300  g for 5
minutes at room temperature. The medium was aspi-
rated and cells were resuspended in fresh medium (5
ml). The suspension was recentrifuged, the cells were
resuspended in medium (0.7 to 1 ml) and transferred to
a Primaria dish (BD Biosciences, San Diego, CA). The
cells were placed in an incubator and left undisturbed
for 5 days.
Cells were confirmed as smooth muscle cells based on
fluorescence staining with -smooth muscle cell actin
antibody and for their reactivity and lack of reactivity
toward calponin and CD31 (platelet endothelial cell ad-
hesion molecule-1, PECAM-1) antibodies, respectively
(see below).47 Cells were grown to confluence in DMEM
supplemented with 10% (v/v) FBS and 1% (v/v) glutamine
in either six-well plates or 100-mm dishes (containing
8.8  106 cells/dish). All cells were incubated at 37°C in
5% CO2 in air. Cells were tested for the presence of
mycoplasma (Mycoplasma PCR ELISA kit; Roche Applied
Science, Indianapolis, IN) with negative results. For ex-
periments with suppressed PGHS-2 expression, cells
were rendered quiescent using DMEM supplemented
with 2% FBS and 1% glutamine for 2 days.48 Cells be-
tween passages one and five were used in experiments.
Detection of Smooth Muscle Cell -Actin and
Calponin in Smooth Muscle Cells Cultured from
ApoE/ and ApoE/iNOS/ Mice by
Fluorescence Staining
Cells were plated onto chamber slides (Lab-Tek; Nunc,
Naperville, IL). When the cells were 50% confluent,
they were washed [phosphate-buffered saline (PBS),
three times] and fixed in methanol at 20°C (5 min-
utes). The cells were washed in PBS (three times),
blocked in 5% rabbit serum (R-7136; 500 l/well for 30
minutes; Sigma Chemical Co., St. Louis, MO) and in-
cubated with primary antibody (monoclonal anti--
smooth muscle actin, clone 1A4, A-2547, 1:200 dilu-
tion; Sigma) in 5% rabbit serum overnight at 4°C. A
control for nonspecific interactions was performed by
incubating cells with an equivalent concentration of
mouse IgG (Sigma). The cells were washed in PBS
(three times, 5 minutes each) and incubated with sec-
ondary antibody (Alexa Fluor 488 rabbit anti-mouse
IgG, A-11078, 1:200 dilution; Molecular Probes, Eu-
gene, OR) in 5% rabbit serum (1 hour at room temper-
ature in the dark). Before the end of the incubation, a
blue fluorescent 4,6-diamidino-2-phenylindole, dihy-
drochloride, nucleic acid stain (2 g/ml) was also
added (5 minutes). The cells were washed (PBS, three
times) and coverslips applied with Vectashield mount-
ing medium (Vector Laboratories, Inc., Burlingame,
CA). The cells were examined using an upright fluores-
cence microscope with appropriate filters (BX51;
Olympus, Melville, NY). All cells defined by 4,6-dia-
midino-2-phenylindole nuclear staining also contained
the selective -smooth muscle actin and were addition-
ally recognized by an antibody directed against the
smooth muscle cell-specific protein calponin (mouse
monoclonal calponin antibody, C-2687; Sigma), but not
by a rat monoclonal antibody against the endothelial
marker CD31 (PECAM-1, SC-18916, Santa Cruz) (data
not shown). Notably, a previous study using an identi-
cal smooth muscle cell isolation method, conserva-
tively estimated the purity of a resulting smooth muscle
cell population at 99%.47 Cells placed in culture are
thought to shift from a contractile to a synthetic phe-
notype that is also adopted by smooth muscle cells
found in the intima during atherosclerosis.49,50 The
cells used in our studies possessed similar levels of
-smooth muscle actin and calponin (which are both
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markers of contractile function51), indicating that they
are in a similar state of differentiation. Cells were main-
tained at low passages (up to passage 5), although we
did not see a significant variation in response to higher
passage number (up to passage 12).
Lipopolysaccharide (LPS)/Interferon (IFN)-
Treatment of Smooth Muscle Cells, PGE2, and
Nitrate/Nitrite Measurements
Smooth muscle cells were preincubated in the presence
and absence of LPS (from Escherichia coli 026:B6, 10
g/ml; Sigma) and recombinant mouse IFN- (100 U/ml;
Calbiochem, La Jolla, CA) for 24 hours to induce PGHS-2
and iNOS gene transcription.52 Culture medium was re-
placed with fresh DMEM (with 1% glutamine and 10% or
2% FBS) and the cells incubated for 30 minutes to 1 hour
at 37°C. The media was removed, stored at 80°C, and
fresh DMEM (with 1% glutamine and 10% or 2% FBS)
containing arachidonic acid (20 mol/L) was added to
the cells for 30 minutes to 1 hour at 37°C. The superna-
tant medium was removed and assayed for PGE2 forma-
tion using an enzyme immunoassay kit (GE Health Care,
Piscataway, NJ) and for nitrate/nitrite production using a
colorimetric assay kit (Cayman Chemical, Ann Arbor, MI).
Total protein in the cell lysate was determined by using
either the Lowry or modified Lowry method.53
Western Blots of Tissue Homogenates and
Smooth Muscle Cells
Lesions and surrounding aortic tissue from ApoE/ and
ApoE/iNOS/ mice were homogenized with a Tissue
Tearor (Dremel, Racine, WI) in a minimum volume (300 to
500 l) of lysis buffer (50 mmol/L Tris-HCl, pH 8, 10
mmol/L EDTA, 1% Tween 20, 10 g/ml aprotinin, 10
g/ml leupeptin, 1 mmol/L phenylmethyl sulfonyl fluoride)
and sonicated. The homogenate was centrifuged (13,000
rpm for 10 minutes at 4°C), and the supernatant was used
for protein assay and Western blotting. Smooth muscle
cells were washed once with PBS and lysed with a lysis
buffer (20 mmol/L Tris-HCl, pH 7.5, 1 mmol/L EDTA, 1
mmol/L EGTA, 150 mmol/L NaCl, 2.5 mmol/L sodium
pyrophosphate, 1 mmol/L -glycerolphosphate, 1
mmol/L sodium orthovanadate, 1 mmol/L phenylmethyl
sufonyl fluoride, 1% Triton X-100, and 1 g/ml leupeptin).
The cells were scraped, transferred to Eppendorf tubes,
vortexed, and placed on ice (30 minutes). Cell lysates
were then sonicated and centrifuged (10,000  g for 10
minutes) for clarification. Cell lysate or tissue protein (15
to 35 g) was separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (10% acrylamide
gel), transferred to a nitrocellulose membrane, blocked
(90 minutes at 25°C or overnight at 4°C) with 5% nonfat
milk in PBS-1% Tween buffer. The membrane was then
probed with primary antibody (for PGHS-1, PGHS-2, or
iNOS) in 1% nonfat milk in PBS-1% Tween buffer accord-
ing to the manufacturer’s recommendations. When using
PGHS-1 antibody (mouse monoclonal, 160110; Cayman
Chemical), the membrane was probed for 1 hour, fol-
lowed by a horseradish peroxidase-conjugated purified
goat anti-mouse antibody for 1 hour. When using PGHS-2
antibody (goat polyclonal, SC-1745; Santa Cruz Biotech-
nology, Santa Cruz, CA), the membrane was probed
either 1 hour or overnight, followed by a rabbit anti-goat
secondary antibody for 1 hour. When using iNOS anti-
body (rabbit polyclonal, SC-650; Santa Cruz), the mem-
brane was probed overnight, followed by a goat anti-
rabbit secondary antibody for 1 hour. Actin (goat
polyclonal, SC-1615, Santa Cruz) or -smooth muscle
actin antibody was used as a measurement of loading
accuracy (90 minutes followed by rabbit anti-goat sec-
ondary antibody). The immunoblot signal was visualized
through chemiluminescence (ECL plus; GE Health Care).
Immunoprecipitation of Nitrated PGHS-1 from
Aortic Lesions and Surrounding Tissue in
ApoE/ and ApoE/iNOS/ Mice
Lesions and surrounding aortic tissue from ApoE/ and
ApoE/iNOS/ mice were homogenized separately
and centrifuged as described above for Western blotting.
The resulting supernatant (1 mg/ml in PBS) was preclari-
fied with Protein G-agarose beads (25 l of a 50% slurry
in PBS for 30 minutes) to reduce nonspecific binding. The
lysate/bead mixture was centrifuged (5000  g for 5
minutes, followed by 16,000  g for 1 minute) to remove
the beads, and the clarified lysate was then incubated
(overnight at 4°C) with polyclonal nitrotyrosine antibody
(Upstate Biotechnology, Lake Placid, NY) followed by
Protein G-agarose beads (35 l of a 50% slurry overnight
at 4°C). The bound agarose beads were collected by
centrifugation (5000  g for 10 minutes, followed by
16,000  g for 1 minute), washed three times with PBS,
and resuspended in Laemmli sample buffer (40 l). The
bead-immunocomplex was boiled (5 minutes), and the
sample (40 l) was separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (10%) and immuno-
blotted with monoclonal PGHS-1 antibody as described
above.
Immunohistochemical Localization of PGHS-1
and iNOS
Immunohistochemistry was performed on frozen aortic
root sections removed from ApoE/ and ApoE/
iNOS/ mice that were maintained on a Western diet
for 4 months. Murine hearts were removed and cryo-
preserved in a 30% sucrose:OCT solution (1:1; Sakura
Finetek USA, Inc., Torrance, CA). Serial frozen sections
were obtained by cryostat sectioning in the region of the
aortic leaflet. The frozen sections were air-dried onto
microscopic slides and were treated with H2O2 (0.1%) in
methanol at 20°C for 30 minutes to quench endoge-
nous peroxidase activity. Adjacent sections were incu-
bated overnight at 4°C with either PGHS-2 (goat poly-
clonal, SC-1745; Santa Cruz) or iNOS (rabbit polyclonal,
SC-650; Santa Cruz) antibodies. Sections were exposed
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at room temperature for 1 hour to biotinylated horse anti-
goat (BA9500; Vector Laboratories) or biotinylated goat
anti-rabbit (BA1000, Vector Laboratories) secondary an-
tibodies, respectively. Immunoreactive proteins were de-
tected using an avidin-biotin-based peroxidase system,
using VIP chromogenic substrate (Vector Laboratories).
Counterstaining was achieved using hematoxylin. Control
sections were treated with PGHS-2 or iNOS antibodies
that were previously incubated with blocking peptides
(SC-1745P, PGHS-2 blocking peptide; SC-650P iNOS
blocking peptide; Santa Cruz) and then developed
as described above. Sections were visualized by light
microscopy, and digital images were captured using an
Olympus microscope.
Double Immunofluorescence of Co-Localized
PGHS-2 and iNOS
Sections, prepared as above, were incubated overnight
at 4°C with both PGHS-1 (goat polyclonal, SC-1754;
Santa Cruz) and nitrotyrosine (rabbit polyclonal, 06284;
Upstate Biotechnology) antibodies. The sections were
exposed at room temperature for 1 hour to a biotinylated
horse anti-goat secondary antibody (BA9500, Vector
Laboratories), followed by exposure to rhodamine/avidin
(A-2012, Vector Laboratories) for visualization of PGHS-1
and to a fluorescein-labeled goat anti-rabbit secondary
antibody (FI-100, Vector Laboratories) for visualization of
nitrotyrosine. Control sections were treated with PGHS-1
and nitrotyrosine antibodies that were previously incu-
bated with a PGHS-1 blocking peptide (SC-1754P, Santa
Cruz) and 3-nitrotyrosine (10 mmol/L). The fluorescence
from immunoreactive proteins was observed by fluores-
cence microscopy and digital images were captured
using an Olympus microscope.
LC-MS/MS Analysis and Database Search
Nanoflow liquid chromatography-tandem mass spec-
trometry (nLC-MS/MS) was used to identify sites of Tyr
nitration in ovine PGHS-1. Ovine PGHS-1 was purified
from sheep seminal vesicles as described previously.54
MS/MS analyses were performed using an 1100 series
LC/MSD XCT plus ion trap mass spectrometer (Agilent,
Palo Alto, CA). The mobile phase contained 0.1% formic
acid in 3% acetonitrile (solvent A) and 0.1% formic acid in
100% acetonitrile (solvent B). PGHS-1 (8 mol/L in 13 l,
containing heme) was incubated with ONOO (1000
mol/L) for 1 hour at ambient temperature. ONOO-
treated and nontreated control proteins were precipitated
in 2 vol of acetone, centrifuged, and then resolubilized in
ammonium bicarbonate (20 mmol/L, pH 8). After reduc-
tion by dithiothreitol (10 mmol/L, 30 minutes at 50°C) and
alkylation by iodoacetamide (50 mmol/L, 30 minutes at
ambient temperature), the samples were digested with
trypsin (sequencing grade, 1:100, trypsin:PGHS-1; Pro-
mega, Madison, WI) for 8 hours at 37°C. Samples were
diluted 100-fold with solvent A, and 8 l of the digested
peptide mixture was injected onto a 0.3  5 mm Zorbax
300SB-C18 enrichment column at a flow rate of 10 l/
minute. Peptides were subsequently resolved on a
0.075  150 mm Zorbax 300SB-C18 analytical column
(3.5 m particle size) at a flow rate of 0.3 l/min with a
gradient of 10 to 40% solvent B for 40 minutes and 40 to
80% solvent B for 30 minutes. Mass spectra were ac-
quired in the automated MS/MS mode, in which MS/MS
scans were performed on the three most intense ions
after each MS scan. The MS/MS spectra were used to
identify the sites of Tyr nitration in PGHS-1 by a database
search using SpectrumMill software (Millenium Pharma-
ceuticals, Cambridge, MA). The parameters for search-
ing were minimum matched peak intensity of 50%, pre-
cursor mass tolerance of 2.5 Da, and product mass
tolerance of 0.7 Da. The program was instructed to ac-
count for Tyr nitration when matching peptide fragments
to PGHS-1.
Isolation of Total RNA and Northern Blotting
Aortic smooth muscle cells cultured from ApoE/ and
ApoE/iNOS/ mice were lysed in RNA-BEE (Tel-Test,
Friendswood, TX). RNA was extracted with chloroform,
and then precipitated with isopropanol. Total RNA from
each sample was loaded on 1% formaldehyde-agarose
gels (20 g/lane). After electrophoresis, RNA was trans-
ferred to a Zeta-probe blotting membrane (Bio-Rad, Her-
cules, CA). The blot was UV cross-linked and prehybrid-
ized with Hybrisol I (Chemicon, Temecula, CA). The blot
was then probed using 32P-labeled PGHS-1, followed by
rehybridization with 32P-labeled GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) to verify that loading
in the wells was equal. The PGHS-1 and GAPDH probes
were kindly provided by Dr. David L. DeWitt (Michigan
State University, East Lansing, MI). The PGHS-2 probe
was kindly provided by Dr. Raymond Dubois (Vanderbilt
University Medical Center, Nashville, TN).
Statistical Analyses
Data are presented as means  SE with significant dif-
ferences determined by t-test, with P  0.05 defined as
statistically significant.
Results
PGHS-2 is Present in Aortic Lesions in ApoE/
and ApoE/iNOS/ Mice but Absent from
the Surrounding Tissue
Figure 1 shows the levels of PGHS-2 and iNOS protein
found by Western blot analysis in the plaque (P) and
surrounding media (M) in aortae removed surgically from
ApoE/ and ApoE/iNOS/ mice after feeding a
Western diet for 6 months. Because the tissue samples
were small, it was necessary to pool samples from sev-
eral mice before analysis. Although PGHS-2 and iNOS
proteins were both present in the aortic plaque of
ApoE/ mice, they were missing or barely detectable in
the media surrounding these lesions. In addition, PGHS-2
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protein was present in the aortic plaque of ApoE/
iNOS/ mice, but absent from the media. Western blot
results confirmed that iNOS protein was missing in both
the plaque and the surrounding media of the ApoE/
iNOS/ mice.
To investigate the potential co-localization of PGHS-2
and iNOS in aortic tissue, immunohistochemical analysis
was performed on aortic root sections from ApoE/ and
ApoE/iNOS/ mice. Immunohistochemical analysis of
aortic sinus lesions demonstrated increased PGHS-2 im-
munoreactivity in the plaque (P) (Figure 2) with little or
no expression in the media (M) in both ApoE/ and
ApoE/iNOS/ mice. iNOS was detected in lesions
from ApoE/ mice, but was missing, as expected, in
aortic sections from ApoE/iNOS/ mice. Some iNOS
staining was also detected in the medial layer of sections
from ApoE/ mice, which is consistent with the obser-
vation that by Western blotting some iNOS was present in
the tissue that surrounds the lesions in ApoE/ mice
(Figure 1). Increased levels of iNOS have previously been
localized to vascular smooth muscle cells and mononu-
clear leukocytes in lesions.55,56 The expression pattern
for both iNOS and PGHS-2 in ApoE/ and ApoE/
iNOS/ lesions was similar to that described by other
investigators.45,46,57
Lesions from ApoE/ Mice Contain Nitrated
PGHS-1 that Is Absent in ApoE/iNOS/
Mice
Immunoprecipitation experiments were performed to de-
termine whether nitrated PGHS accumulates in aortic
tissue obtained from ApoE/ and ApoE/iNOS/
mice. Animals were maintained on a Western diet for 6
months, and aortic tissue was dissected under a micro-
scope into portions comprising the plaque (P) and sur-
rounding media (M). Because the tissue samples were
small, it was necessary to pool samples from several
mice for ample immunoprecipitation of PGHS-1. Anti-
oxidants were added to limit potential ex vivo oxidation.
Lesions were readily visualized and were commonly 1
mm in length but sometimes reached 3 to 4 mm. For
every immunoprecipitation experiment, tissues were
pooled from 10 ApoE/ and 10 ApoE/iNOS/
mice, providing 300 g of total protein. Nitrated pro-
teins from the atherosclerotic plaque and surrounding
media were immunoprecipitated using a polyclonal 3-ni-
trotyrosine antibody. Immunoprecipitated proteins were
resolved by gel electrophoresis and immunoblotted with
a PGHS-1 monoclonal antibody (Figure 3). Although ni-
trated PGHS-1 was observed in the plaque from ApoE/
mice, little or no PGHS-1 nitration was detected in plaque
obtained from the ApoE/iNOS/ animals. In addition,
the surrounding media showed little or no evidence of
PGHS-1 nitration in either the ApoE/ or ApoE/
iNOS/ mice. These data indicate that lesional PGHS-1
undergoes significant Tyr nitration in vivo and iNOS is the
principal source of NO required for this modification.
Surprisingly, on stripping of blots and reprobing for
PGHS-2, we did not observe PGHS-2 nitration (data not
shown).
To confirm that PGHS-1 is nitrated in situ, double-label
immunofluorescence imaging was performed on sections
Figure 1. PGHS-2 is present in aortic plaque in ApoE/ and ApoE/
iNOS/ mice but is absent in the surrounding medial tissue. Western blot
demonstrating PGHS-2 and iNOS protein levels in atherosclerotic plaque (P)
and surrounding media (M) removed from ApoE/ (1) and ApoE/
iNOS/ (2) mice after 6 months on a Western diet. Actin protein levels are
also included to demonstrate equal loading of wells. The results shown were
obtained by pooling tissue from 11 ApoE/ and 19 ApoE/iNOS/ mice.
The results from this experiment have been reproduced three times from
three different pools of tissue.
Figure 2. A comparison of PGHS-2 and iNOS localization in aortic sinus
lesions from ApoE/ and ApoE/iNOS/ mice. Immunohistochemical
detection of iNOS and PGHS-2 in aortic sinus lesions from ApoE/ (top)
and ApoE/iNOS/ (bottom) mice fed a Western diet for 4 months. L,
lumen; P, plaque; M, media; con, control sections stained with antibody
preincubated with antigen. Sections were counterstained with hematoxylin
to visualize nuclei. Similar results were observed in aortic sinus lesions from
three ApoE/ and three ApoE/iNOS/ mice.
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of murine hearts from ApoE/ and ApoE/iNOS/
mice fed a Western diet for 4 months. Double immuno-
fluorescence detected PGHS-1 (Figure 4a) and nitroty-
rosine (Figure 4b) in lesions of the ApoE/ mouse. The
overlay demonstrated co-localization of PGHS-1 and ni-
trotyrosine in lesions of the ApoE/ mouse (yellow; indi-
cated by arrows in Figure 4c). In contrast, in lesions of
ApoE/iNOS/ mice, PGHS-1 was present in the
plaque (Figure 4d), but nitrotyrosine levels were low (Fig-
ure 4e). Moreover, co-localization of PGHS-1 and nitroty-
rosine in ApoE/iNOS/ mice was reduced (Figure 4f).
These data indicate that nitrated PGHS-1 predominates
in the plaque of lesions obtained from ApoE/ mice
relative to ApoE/iNOS/ mice, although the presence
of some nitrated PGHS-1 in aortic lesions of ApoE/
iNOS/ mice cannot be discounted.
Reaction of PGHS-1 with Peroxynitrite Results
in 3-Nitrotyrosine Accumulation at Tyr385
We previously demonstrated that purified PGHS-1 can be
nitrated by ONOO.29 Spectroscopic data indicated that
ONOO nitrates 2 Tyr residues/PGHS-1 monomer.29,58
To identify which Tyr residues were nitrated, ONOO-
treated purified PGHS-1 was subjected to trypsinolysis
and analyzed by nLC-MS/MS. PGHS-1 was incubated
with ONOO (1 mmol/L) for 1 hour and isolated by ace-
tone precipitation. PGHS-1 was resuspended in ammo-
nium bicarbonate, reduced, and alkylated (see Materials
and Methods). Solubilized PGHS-1 was proteolyzed with
0.3% trypsin, followed by peptide analysis using nLC-
MS/MS (Figure 5). Figure 5a shows the extracted ion
chromatograms for the ONOO-treated PGHS-1 and
control PGHS-1 samples of a fragment corresponding to
m/z (645.6) of the quadruply charged peptide ion IA-
MEFNQLYHWHPLMPDSFR (Ile377 to Arg396), which is
nitrated on Tyr385. Notably, this nitrated peptide from
ONOO-treated PGHS-1 (38 minutes, indicated by an
arrow) was undetectable in nontreated, control PGHS-1.
Tandem mass spectrometric analysis of this peptide (Fig-
ure 5b) confirms that this peak indeed represents the
tryptic peptide containing nitrated Tyr385. Several y- and
b-series ions are observed, including a long, continuous
series of y ions that stretches from y12 to y19 of this
peptide fragment. It is notable that the fragmentation
pattern of peptides is sequence-dependent, and many
peptides do not display an ideal fragmentation pattern
with a more complete b- and y-ion series. This is partic-
ularly relevant for a peptide such as IAMEFNQLYHWH-
PLMPDSFR, which contains two Pro and two His resi-
dues. It is well known that both of these residues induce
atypical fragmentation.59 With two His and Pro each in
the sequence, it is, therefore, not surprising that the frag-
mentation pattern observed for this peptide is somewhat
limited. Figure 5b shows that the MS/MS spectrum is
dominated by a triply charged y18 ion at m/z  798.9, in
accord with the presence of two positively charged His
residues in the sequence. The identity of this ion is further
supported by another strong peak at m/z  599.4 repre-
senting the quadruply charged ion of the same fragment.
The strong dominancy of this particular fragment may
account for the relatively less complete ion series de-
tected. In a previously published tandem mass spectro-
metric study of a variant form of the human hemoglobin 
chain, a very similar fragmentation pattern of a quadruply
charged tryptic peptide ion bearing two His residues was
observed: the MS/MS was dominated by a few triply
charged y ions near the N terminus, with incomplete b-
and y-ion series.60 Site-directed mutagenesis studies
have demonstrated that Tyr385 is essential to cyclooxy-
genase activity.61,62 Technical limitations have precluded
the rigorous MS/MS-based structural characterization of
PGHS-1 from lesional tissues, owing mainly to the very
limited amount of available tissue. These data establish
that ONOO selectively nitrates Tyr385 in PGHS-1, but it
is not yet known whether this specific Tyr residue is
nitrated in PGHS-1 in atherosclerotic tissue, and if so,
whether this is the preferred Tyr residue that undergoes
nitration under biological conditions.
Smooth Muscle Cells Cultured from ApoE/
iNOS/ Mice Express Significantly Higher
Levels of PGHS-1 and PGHS-2 Protein and
mRNA than Smooth Muscle Cells from ApoE/
Mice
Smooth muscle cells were cultured from ApoE/ and
ApoE/iNOS/ mice to examine the levels of PGHS-1
and PGHS-2 expressed. Cells were maintained in FBS,
which has previously been shown to induce PGHS-2 in
rat smooth muscle cells.48,63 To determine the effect of
serum on PGHS-2 expression, smooth muscle cells were
grown in media containing 10% FBS, which was then
replaced with 2% FBS. Figure 6 demonstrates that
PGHS-2 was expressed when smooth muscle cells from
ApoE/ mice were incubated in media containing 10%
Figure 3. Lesions from ApoE/ mice contain nitrated PGHS-1 that is re-
duced in ApoE/iNOS/ mice. Aortic tissue from ApoE/ and ApoE/
iNOS/ mice fed a Western diet for 6 months was dissected into portions
representing the plaques (P) and noninvolved surrounding medial tissue
(M). The tissue was homogenized as described in the Materials and Methods.
Proteins containing 3-nitrotyrosine were immunoprecipitated using a poly-
clonal 3-nitrotyrosine antibody and then immunoblotted with a PGHS-1
monoclonal antibody. This experiment has been reproduced three times
using three different pools of tissue. Each tissue pool is from 10 ApoE/
and 10 ApoE/iNOS/ mice.
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FBS (day 0). However, PGHS-2 levels progressively di-
minished with time when replaced by 2% FBS (days 1 to
4). Thus, smooth muscle cells cultured in FBS express
PGHS-2.
Western blot analyses were performed on smooth
muscle cells from ApoE/ and ApoE/iNOS/ mice
cultured under identical conditions to determine the rel-
ative expression of PGHS-1 and PGHS-2 protein levels.
Figure 7 shows that significantly higher levels of both
PGHS-1 (Figure 7a) and PGHS-2 (Figure 7b) protein were
found in aortic smooth muscle cells obtained from adult
ApoE/iNOS/ mice compared to ApoE/ mice. Un-
der these conditions, iNOS protein was missing in the
ApoE/iNOS/ smooth muscle cells, but traces were
occasionally detected by Western blotting in the ApoE/
cells (data not shown). Under quiescent conditions (ie, in
DMEM containing 2% FBS), PGHS-1 protein levels were
also significantly higher in smooth muscle cells from
ApoE/iNOS/ mice compared to ApoE/, although
no differences were observed in the low levels of PGHS-2
(data not shown). Figure 7 also shows that significantly
higher levels of PGHS-1 (Figure 7c) and PGHS-2 (Figure
7d) mRNA levels were expressed in cells obtained from
ApoE/iNOS/ mice compared to ApoE/ control
mice (when normalized to GAPDH mRNA levels).
Smooth Muscle Cells Cultured from ApoE/
and ApoE/iNOS/ Mice Produce
Significantly Different Levels of Eicosanoids
Smooth muscle cells cultured from ApoE/ and ApoE/
iNOS/ mice were exposed to arachidonic acid (20
mol/L) and the supernatant medium was analyzed for
Figure 4. PGHS-1 and nitrotyrosine co-localize in aortic sinus lesions from ApoE/ mice. Double-immunofluorescence detection of PGHS-1 and nitrotyrosine
in aortic sinus lesions removed from ApoE/ (a–c) and ApoE/iNOS/ (d–f) mice maintained on a Western diet for 4 months. For visualization of PGHS-1,
sections were incubated with a goat polyclonal PGHS-1 antibody followed by exposure to a biotinylated horse anti-goat secondary antibody and a rhodamine/
avidin mixture. Sections were co-incubated with a fluorescein-labeled goat anti-rabbit secondary antibody for visualization of nitrotyrosine. The left sides of these
panels depict autofluorescence from the internal elastic lamina in the media. Asterisks denote areas of nonspecific binding or autofluorescence. Insets (bottom
parts of a, b, d, and e) represent control sections in which the PGHS-1 and nitrotyrosine antibodies were pretreated with a PGHS-1 blocking peptide and
3-nitrotyrosine (10 mmol/L), respectively. PGHS-1 and nitrotyrosine co-localization was assessed in aortic sinus sections from three ApoE/ and three
ApoE/iNOS/ mice.
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PGE2 formation. Figure 8 shows that in the absence of
added arachidonic acid, basal levels of PGE2 produced by
cultured ApoE/ and ApoE/iNOS/ smooth muscle
cells were low. On addition of arachidonic acid (20 mol/L),
increased levels of PGE2 were produced in both cases
compared to basal levels. However, ApoE/iNOS/
smooth muscle cells produced significantly higher levels of
PGE2 compared to ApoE
/ smooth muscle cells. After
incubation with IFN- and LPS, which are known to syner-
gistically induce both PGHS-2 and iNOS expression,52 sig-
nificantly higher levels of PGE2 were once again observed
in the supernatant medium from ApoE/iNOS/ com-
pared to ApoE/ smooth muscle cells after arachidonic
acid addition (20 mol/L). When challenged with LPS/IFN-,
ApoE/ and ApoE/iNOS/ smooth muscle cells pro-
duced similar levels of PGHS-2 with no significant differ-
ences (data not shown). Nitrite/nitrate production and iNOS
expression under these conditions, however, was observed
in ApoE/ mice but not in ApoE/iNOS/ mice (data not
shown). Interestingly, there was no significant difference
between PGE2 produced by arachidonic acid-stimulated
ApoE/iNOS/ cells in the presence or absence of LPS/
IFN-, suggesting that the ApoE/iNOS/ cells produce
maximal levels of PGHS-2.
These data indicate that significantly higher PGE2 lev-
els were produced by smooth muscle cells cultured from
ApoE/iNOS/ than ApoE/ mice. This result is con-
sistent with the observation that ApoE/iNOS/ cells
express more PGHS-1 and PGHS-2 mRNA and protein
than ApoE/ cells. In addition, smooth muscle cells
cultured from ApoE/iNOS/ mice were maximally
stimulated with respect to PGHS-2 expression and were
Figure 5. Peroxynitrite nitrates purified PGHS-1 at Tyr385. Purified ovine PGHS-1 (8 mol/L) was incubated with peroxynitrite (ONOO; 1 mmol/L) for 1 hour
and subjected to acetone precipitation, resuspension in ammonium bicarbonate, and reduction and alkylation (as described in Materials and Methods). A control
PGHS-1 sample was prepared in a similar manner. The samples were digested with 0.3% trypsin overnight and analyzed by nLC-MS/MS. a: Extracted ion
chromatograms for the peptide fragment (m/z  645.6) representing the quadruply charged peptide IAMEFNQLYHWHPLMPDSFR that is nitrated at the Tyr
residue. The top and bottom extracted ion chromatograms monitor this peptide fragment with time for the ONOO-treated and control PGHS-1 samples,
respectively. The arrow at 38 minutes in the top profile indicates the presence of a peak that is missing in the control PGHS-1 sample. b: MS/MS analysis of
the peptide fragment at 38 minutes confirms the identity of this peptide sequence as IAMEFNQLYHWHPLMPDSFR containing nitrated Tyr385. The black
diamond at m/z  645.6 indicates the position of the precursor fragment from which the ions observed are derived.
Figure 6. Serum induces PGHS-2 in smooth muscle cells. Aortic smooth
muscle cells were cultured from ApoE/ mice as described in Materials and
Methods. The cells were grown to 80% confluency in DMEM containing
10% FBS (lane 0) and in DMEM containing 2% FBS for 1, 2, 3, or 4 days
(lanes 1–4, respectively). The cells were lysed, analyzed by Western blot-
ting, and probed for PGHS-2, followed by actin. Std represents standard
purified ovine PGHS-2.
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not influenced by the addition of LPS/IFN-. Although
LPS/IFN- challenge in ApoE/ smooth muscle cells
produced a modest increase in PGE2 over basal levels,
the levels produced did not match those achieved by the
ApoE/iNOS/ cells. These results further suggest a
regulatory role of iNOS on PGHS activity.
Discussion
This study demonstrates for the first time that iNOS influ-
ences PGHS expression and activity and contributes to
PGHS-1 nitration during the disease state of atheroscle-
rosis. Owing to the numbers of mice required for this
study, both male and female ApoE/ and ApoE/
iNOS/ mice were used and no attempt was made to
determine the effects of gender.
PGHS-2 and iNOS have previously been observed in
human atherosclerotic tissue,5,6,64–66 and levels of
PGHS-2 were also found to be increased in murine ath-
erosclerotic aortae.57,67 In this current study, we demon-
strate that PGHS-2 is present in the murine atheroscle-
rotic lesions of ApoE/ and ApoE/iNOS/ mice fed a
Western diet for 6 months but is absent in the tissue
surrounding the lesion. In addition, we show that iNOS is
induced in lesions in ApoE/ mice and is virtually absent
in the surrounding tissue. As expected, iNOS is absent in
both lesions and surrounding noninvolved tissues ob-
tained from the ApoE/iNOS/ mice.
We have previously observed PGHS-1 nitration in human
atherosclerotic tissue obtained from endarterectomies.29
We now report that PGHS-1 is nitrated in lesions obtained
from ApoE/ mice but markedly less so in lesions from
ApoE/iNOS/ mice. Notably, immunofluorescence data
does not exclude the possibility that PGHS-1 nitration may
occur at low levels in the absence of iNOS. Accordingly,
eNOS may contribute to PGHS-1 nitration, although
PGHS-1 nitration is primarily dependent on iNOS protein
expression. The coincidental lack of PGHS-1 nitration and
iNOS in the surrounding noninvolved aortic tissue in the
ApoE/ mouse seems to suggest, however, that PGHS-1
nitration is iNOS-dependent.
Our data demonstrate that iNOS is involved in PGHS-1
nitration at the site of the atherosclerotic lesion and that
iNOS provides the first step in a mechanism of PGHS-1
nitration. NO release from iNOS could combine with su-
peroxide to form peroxynitrite (ONOO), a reactive spe-
cies with enhanced oxidizing capability.68,69 Of the
deleterious effects, ONOO has been implicated in myo-
cardial reoxygenation injury,70 initiating lipid peroxidation
of membranes,71 reacting with sulfhydryl groups of pro-
teins,72 and causing oxidative damage by introducing
Tyr nitration.73 We have previously demonstrated that
ONOO causes nitration of purified PGHS-1 and PGHS-1
in smooth muscle cells.29 In this study, we now identify
Tyr385 as a specific site of nitration by ONOO in purified
PGHS-1 by mass spectrometry. Tyr385 is located at the
Figure 7. PGHS-1 and PGHS-2 protein and mRNA levels are significantly
higher in smooth muscle cells cultured from ApoE/iNOS/ than
ApoE/ mice. Aortic smooth muscle cells were cultured from ApoE/ and
ApoE/iNOS/ mice as described in Materials and Methods. The cells
were grown to confluency in DMEM containing 10% FBS, then lysed and
analyzed in triplicate for PGHS-1 (a) and PGHS-2 (b) protein by Western
blotting. In each case, the blot was also probed for actin. The bar graphs
represent the protein/actin ratio for a and b. The results are representative of
one experiment (with three replicates) that was repeated three times. RNA
was also isolated from ApoE/ and ApoE/iNOS/ smooth muscle cells
that were cultured in DMEM containing 10% FBS. c: After isolation, RNA (20
g per lane) was loaded onto a gel in triplicate and separated by electro-
phoresis, transferred to a nylon membrane, and hybridized with a 32P-labeled
probe for PGHS-1 to yield a signal at 2.8 kb. The blot was then rehybridized
with a 32P-labeled GAPDH cDNA probe (signal at 1.3 kb). d: The same blot
was later rehybridized with a 32P-labeled cDNA probe for PGHS-2 to yield a
signal at 4.3 kb. The bar graphs represent the PGHS-1/GAPDH (c) and
PGHS-2/GAPDH (d) ratios. The results are representative of one experiment
repeated twice.
Figure 8. PGE2 production is significantly higher in ApoE
/iNOS/ than
in ApoE/ smooth muscle cells. Aortic smooth muscle cells were cultured
from ApoE/ and ApoE/iNOS/ mice as described in Materials and
Methods. The cells were grown in DMEM containing 10% FBS to 90%
confluency, and then incubated in DMEM with and without LPS (10 g/ml)
and IFN- (100 U/ml) at 37°C. After 24 hours, the supernatant was replaced
with fresh DMEM containing 10% FBS and the cells incubated at 37°C. After
1 hour, the medium was removed and stored at 80°C. The cells were then
exposed to DMEM (10% FBS) containing arachidonic acid (20 mol/L) and
incubated at 37°C. After 1 hour, the supernatant was removed and stored at
80°C. The supernatants were analyzed for PGE2 formation. The data rep-
resent the average from three experiments in which three measurements
were recorded per experiment.
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apex of the cyclooxygenase binding channel and is
thought to be involved in the catalytic mechanism of
PGHS enzymes.61,62 Tyr385 is involved in radical forma-
tion that initiates arachidonic acid oxygenation, leading to
eicosanoid formation,74,75 although the radical may also
be localized on a different Tyr residue.62,76–79 Nitration of
Tyr385 would predictably lead to a complete loss of
arachidonic acid metabolism.61 Although NO has previ-
ously been demonstrated to couple with the Tyr385 rad-
ical of PGHS-1,80 leading to the eventual nitration of
Tyr385,81 this represents the first identification of a spe-
cific nitrated Tyr residue in PGHS-1 by ONOO.
Under pathophysiological conditions, ONOO forma-
tion may occur, because both iNOS expression and su-
peroxide production are concomitantly elevated,64,65,82
and the rate of ONOO production (6.7  109 mol/
L1second1) outcompetes the rate at which superoxide
dismutase scavenges superoxide (2  109 mol/
L1second1).68,83 Thus, the presence of ONOO dur-
ing atherosclerosis seems likely, although doubts over its
formation under physiological or pathophysiological con-
ditions persist.84–86 Other mechanisms can also lead to
nitrotyrosine formation. For instance, peroxidase en-
zymes (eg, myeloperoxidase, MPO) can use nitrite
(NO2
) and hydrogen peroxide (H2O2) as substrates to
catalyze tyrosine nitration in proteins.87–89 The MPO/
NO2
/H2O2 system has been demonstrated to nitrate
and to cause LDL oxidation, which may contribute to the
development of atherosclerosis.90 On the other hand,
others have shown that MPO/ mice show greater levels
of nitrotyrosine formation (and larger infarct volumes)
than wild-type mice, leading to the conclusion that the
presence of MPO counters nitration.91 In the absence of
a peroxidase, NO2
 and H2O2 can nitrate at low pH
(2).92 Nitrotyrosine formation in proteins may also occur
in the presence of hypochlorous acid (HOCl) and NO2
,
but this reaction also yields 3-chlorotyrosine,93,94 which
may also cause oxidative damage in tissues.95 Despite
these alternative mechanisms, nitration of Tyr residues in
proteins produces a stable end-product that can be de-
tected immunologically. Identification of nitrated PGHS-1
in lesions from ApoE/ mice by mass spectrometry has
not yet proven feasible (due to the large amounts of
tissue required coupled with the necessity of having rea-
sonably pure samples), but it is the subject of ongoing
efforts. Further studies will be required to elucidate the
mechanism by which Tyr nitration in PGHS-1 occurs in
atherosclerotic tissue and whether Tyr385 in PGHS-1
represents a physiological target for nitration.
We have previously demonstrated that PGHS nitration
coincides with a loss in activity,29 but it is unclear whether
the extent of nitration and associated loss in function
contributes to the progression of atherosclerosis. Surpris-
ingly, PGHS-2 nitration was not detected, suggesting that
this modification does not occur to a significant extent or
possibly that antibodies used are not sufficiently sensitive
for detection. Although it is generally assumed that
PGHS-2 is the most important isozyme in atherosclerosis
and inflammation, PGHS-1 may also play a key role in
maintaining the balance of eicosanoids during this dis-
ease state.67
Previous studies have found that endothelial NO syn-
thase (eNOS) is an important regulator of vascular func-
tion. Thus, ApoE/eNOS/ mice were found to have
higher blood pressure and increased atherosclerotic le-
sion size compared to normotensive, atherosclerotic
ApoE/ mice.44 The lack of eNOS in ApoE/ mice
caused them to develop kidney damage and have de-
creased kidney weight with glomerular lipid deposition
and calcification.44 The inducible form of NOS is usually
absent in nondiseased vessels, and thus may not be
expected to contribute to vascular function under normal
conditions. However, under conditions of inflammation,
iNOS is induced and is capable of generating NO, pos-
sibly in the m range.96 A genetic lack of iNOS in
ApoE/ mice does not affect blood pressure nor alter
the development of atherosclerotic lesions as compared
to ApoE/ mice when fed a normal chow diet.44 How-
ever, when ApoE/iNOS/ mice are fed a high-fat diet,
the atherosclerotic lesions are diminished in size com-
pared to ApoE/ mice.45,46 Our experience from per-
forming immunoprecipitation experiments indicated that
lesions from 5 ApoE/ and 9 ApoE/iNOS/ mice
(at 6 months on a high cholesterol diet) typically provided
enough protein for one such experiment. The difference
in the numbers of mice required likely reflects the fact that
less lesion formation occurs in ApoE/iNOS/ mice
than in ApoE/ mice fed a Western diet46 and indicates
that iNOS contributes to lesion size under these dietary
conditions (possibly via protein nitration). Cholesterol,
cholesteryl esters, and lipoperoxides (a marker for oxida-
tive stress) have been found to be significantly dimin-
ished in ApoE/iNOS/ mice compared to ApoE/
mice.45,46 These results indicate that iNOS contributes to
the size of atherosclerotic lesions in ApoE/ mice, per-
haps by promoting inflammation and oxidative stress at
the site of the lesion.
Finally, we show that smooth muscle cells cultured
from ApoE/iNOS/ mice express significantly higher
levels of PGHS-1 and PGHS-2, as well as increased
levels of PGE2, compared to those cultured from ApoE
/
mice. Cells challenged with LPS and IFN-, immunoacti-
vators known to induce iNOS as well as PGHS-2, did not
boost PGE2 levels in ApoE
/ cells to the high levels
obtained from ApoE/iNOS/ cells. Northern blot anal-
ysis of PGHS-1 and PGHS-2 mRNA demonstrated that
both PGHS-1 and PGHS-2 transcription are elevated in
ApoE/iNOS/ compared to ApoE/ smooth muscle
cells. The effect of iNOS deletion on eicosanoid produc-
tion has previously been studied in mice.30 It was found
that PGE2 production was decreased in peritoneal mac-
rophages and in urine obtained from iNOS/ mice com-
pared to wild-type mice. These observations are consis-
tent with NO or NO-derived species having a stimulatory
effect on PGHS in inflammatory cells and in the kidney.
Indeed, ONOO is known to stimulate purified PGHS and
PGHS in cells16,17 and could explain why higher levels of
urinary and macrophage eicosanoids are observed in
wild-type mice. Our current study investigated the effect
of iNOS deletion in a mouse model of atherosclerosis (ie,
using ApoE/ mice). Previous investigations have dem-
onstrated that urinary eicosanoid levels are elevated in
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human and murine atherosclerosis (using either ApoE/
or low-density lipoprotein receptor knockout, LDLR/,
mice).9–11 Although the measurement of urinary eico-
sanoids represents a noninvasive method, the levels are
not specific to the tissue of origin of these compounds.
We chose, therefore, to investigate levels of eicosanoids
produced by smooth muscle cells cultured from both
ApoE/ and ApoE/iNOS/ mice. Surprisingly, we
have observed that iNOS deletion in ApoE/ mice has a
stimulatory effect on PGHS-1 and PGHS-2 pretransla-
tional levels. Others have demonstrated that in the ab-
sence of eNOS, other vasodilator pathways compensate
to maintain near-normal coronary arterial function.39 In
this regard, coronary arteries from wild-type mice re-
sponded to acetylcholine by a mechanism involving NO
from eNOS; however, coronary arteries from eNOS/
mice dilated by a mechanism dependent on PGHS.
These observations suggest a compensatory ability by
PGHS in response to chronic loss of NOS, which has also
been reported by others.34–38 It is conceivable that
mechanisms may exist that compensate for the lack of
iNOS. Because PGHS-mediated PGE2 production is in-
creased in cultured ApoE/iNOS/ versus ApoE/
(iNOS-expressing) mouse aortic smooth muscle cells, we
infer that iNOS can markedly suppress PGHS activity in
vascular cells. The extent to which iNOS-dependent ni-
tration of Tyr in PGHS-1 contributes to perturbed eico-
sanoid biosynthesis in human atherosclerotic lesions
awaits future investigations.
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